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Abstract  
A novel multi-organ disease that is fatal in early childhood was identified in three patients 
from two non-consanguineous families. These children were born asymptomatic but at the 
age of two months they manifested progressive multi-organ symptoms resembling no 
previously known disease. The main clinical features included progressive 
cerebropulmonary symptoms, malabsorption, progressive growth failure, recurrent 
infections, chronic haemolytic anaemia and transient liver dysfunction. In the affected 
children, a neuropathology revealed increased angiomatosis-like leptomeningeal, cortical 
and superficial white matter vascularisation and congestion, vacuolar degeneration and 
myelin loss in white matter, as well as neuronal degeneration. Interstitial fibrosis and 
previously undescribed granuloma-like lesions were observed in the lungs. Hepatomegaly, 
steatosis and collagen accumulation were detected in the liver.  
A whole-exome sequencing of the two unrelated families with the affected children 
revealed the transmission of two heterozygous variants in the NHL repeat-containing 
protein 2 (NHLRC2); an amino acid substitution p.Asp148Tyr and a frameshift 2-bp 
deletion p.Arg201GlyfsTer6. NHLRC2 is highly conserved and expressed in multiple 
organs and its function is unknown. It contains a thioredoxin-like domain, however, an 
insulin turbidity assay on human recombinant NHLRC2 showed no thioredoxin activity. 
In patient-derived fibroblasts, NHLRC2 levels were low, and only p.Asp148Tyr was 
expressed. Therefore, the allele with the frameshift deletion is likely non-functional. 
Development of the Nhlrc2 null mouse strain stalled before the morula stage. Morpholino 
knockdown of nhlrc2 in zebrafish embryos affected the integrity of cells in the midbrain 
region.   
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This is the first description of a fatal, early-onset disease; we have named it FINCA disease 
based on the combination of pathological features that include fibrosis, neurodegeneration, 
and cerebral angiomatosis.  
 
Keywords: central nervous system, cerebropulmonary disease, multi-organ disease, 
interstitial fibrosis, neurodegeneration, brain angiogenesis 
 
Introduction 
Recent developments in network-based approaches have led to the discovery of disease-
causing genes, the unexpected links between apparently unrelated diseases, diagnostic 
biomarkers and therapeutic targets for cancer, diabetes and several neurodegenerative 
diseases including Alzheimer's, Parkinson's, and Huntington's diseases [1,22]. Rare, 
inherited mutations causing familial neurodegenerative diseases provide the molecular 
basis for the cellular pathways underlying the pathogenesis of diseases, including the 
accumulation of aberrant or misfolded proteins, protofibril formation, ubiquitin-
proteasome system dysfunction, excitotoxic insult, oxidative and nitrosative stress, 
mitochondrial injury, synaptic failure, altered metal homeostasis and failure of axonal and 
dendritic transport [2].  Chronic, progressive pulmonary disorders include interstitial 
fibrosis, granulomatous changes and diffuse alveolar damage caused by various 
pathogenetic and genetic mechanisms [25]. However, the current understanding of the 
molecular basis of degenerative disease–related mechanisms, such as tissue fibrosis, 
neurodegeneration and angiogenesis, remains incomplete.  
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 The research field focusing on molecular genetic aetiologies and cellular mechanisms 
of inherited human diseases has undergone a major revolution in the last decade because 
of modern research technology that includes whole-exome sequencing (WES) and 
bioinformatic analyses, which provide better means to identify novel proteins, cellular 
pathways and disease mechanisms. Herein, we characterise a novel, early-onset and 
progressive multi-organ disease presenting mainly as severe cerebropulmonary 
manifestations that eventually led to death in infancy. We present the clinical, radiological 
and histological characterisations of this multi-organ disease, which we named FINCA 
disease based on the unique histopathological findings of the patients (fibrosis, 
neurodegeneration, and cerebral angiomatosis). According to our WES analysis, all three 
affected children with FINCA disease harboured an identical combination of variants in 
the NHL repeat containing 2 (NHLRC2) gene encoding NHLRC2, a protein with a 
thioredoxin-like domain. However, its function is currently uncharacterized, enabling no 
direct biochemical assay to address the pathological role of the variants identified. To 
acquire more information about the function of NHLRC2 in vivo, we studied the effects of 
knocking out or down the expression of Nhlrc2 in mice and zebrafish models, respectively. 
Finally, our data suggests that NHLRC2 is an important factor in the maintenance of multi-
organ homeostasis, indicating a wider role for NHLRC2 in the pathogenesis of 
degenerative human diseases. 
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Materials and methods 
Study subjects  
As part of the diagnostic protocol, skin and skeletal muscle biopsy samples were collected 
from three patients with severe, early-onset undefined progressive cerebropulmonary and 
multi-organ disease. The patients were examined at the Department of Paediatrics of Oulu 
University Hospital from 2001–2003 (Patients 1 and 2 from Family A) and 2010–2011 
(Patient 3 from Family B). Investigations included clinical assessments and radiological, 
histological, biochemical and molecular genetic analyses. Based on the severe, multi-organ 
phenotype, a mitochondrial disease was suspected, and muscle biopsies were performed; 
however, there were no specific abnormal findings. Mitochondrial respiratory chain 
enzyme activities were normal, there were no deletions in muscle mitochondrial DNA and 
the sequencing of the coding region of mtDNA revealed no pathogenic variants or exons 
and exon–intron boundaries of the genes encoding mitochondrial twinkle helicase and 
polymerase gamma. Furthermore, CLN1, NKX2-1, SFTPB, ABCA-3 and SFTPC genes 
were sequenced to exclude infantile neuronal ceroid lipofuscinosis, brain–lung–thyroid 
syndrome and gene defects related to surfactant proteins; no pathogenic variants were 
found in these genes. The disease course was progressive, leading to the early deaths of all 
the patients.  
 
Histopathological studies of tissue samples (Electronic Supplementary Material) 
Tissue biopsies (lung and skeletal muscle biopsies) and autopsy samples were obtained 
from all three affected patients. The tissue was fixed in buffered 4% formaldehyde, 
routinely processed into paraffin blocks and cut into 5.0 μm sections. Hematoxylin-eosin 
7 
 
and luxol fast blue stainings were performed as previously described [8] 
 
Transmission electron microscopy on patient tissue samples and zebrafish nhlrc2 
morphants 
Autopsy samples from the lungs and liver from Patient 2 and whole zebrafish embryos at 
2 dpf injected with random sequence (5.1 ng) or splice site-blocking morpholino (5.0 ng) 
were fixed in 1% glutaraldehyde and 4% formaldehyde in 0.1 M phosphate buffer and were 
then post-fixed with 1% osmium tetroxide (Electron Microscopy Sciences, Hatfield, PA, 
USA), dehydrated in acetone and embedded in Epon LX112 (#21210; Ladd Research 
Industries Inc., Williston, VT, USA). Thin sections were cut with a Leica Ultracut UCT 
microtome (FC6; Leica, Wetzlar, Germany), stained with uranyl acetate (Structure Probe 
Inc., West Chester, PA, USA) and lead citrate (Laurylab, Brindas, France) and examined 
with a Tecnai Spirit transmission electron microscope (FEI Company, Eindhoven, 
Netherlands). Images were captured with a Quemesa CCD camera (Olympus Soft Imaging 
Solutions, Münster, Germany). Specimens for electron microscopy were processed and 
analysed in the EM core facility at Biocenter Oulu (Oulu, Finland).  
 
Molecular genetic analyses and genealogy (Electronic Supplementary Material) 
Whole exome sequencing (WES) [26] and bioinformatics analysis [31] were performed on 
samples from both families. Using Sanger sequencing, we confirmed variants and 
segregation within the families. To investigate the heredity of the mutations, we traced the 
ancestors of the patients in the Finnish Population Registries and National Archives of 
Finland [30].  
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Screening of NHLRC2 variants in population cohorts  
To determine whether the two NHLRC2 variants were present in the general Finnish 
population, we used two strategies. First, we examined these variants in a Finnish 
population of infants born at term (gestational age ≥37 wk, total n=306) sampled 
prospectively at Oulu University Hospital from 2004 to 2007 (n = 199) [11]
 
and in 2014 (n 
=107). The individuals born in this hospital mostly originate from northern Finland; 
therefore, these infants represent a valid population control. Next, we searched the 
Sequencing Initiative Suomi (SISu) [7] and ExAC data [14] (http://exac.broadinstitute.org/ 
;01,2017) for the variants.  The SISu data currently covers exonic variants of 10,490 
individuals of Finnish origin. 
 
NHLRC2 expression and function (Electronic Supplementary Material) 
After reverse-transcription PCR (RT-PCR), we used Sanger sequencing to investigate the 
expression of the mutant alleles. Protein expression in the whole-cell extracts of fibroblasts 
from all three patients and healthy control subjects, together with the homogenates of 
control autopsy samples from several types of human tissues, were analysed by 
immunoblotting. Two constructs containing either full-length human NHLRC2 or the 
thioredoxin-like domain alone were expressed in the E. coli strain BL21 (DE3). An insulin 
turbidity assay to test thioredoxin activity was performed, as previously described [10].   
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Nhlrc2 knockout mice (Electronic Supplementary Material) 
Heterozygous C57BL/6N-Atm1Brd Nhlrc2tm1a(KOMP)Wtsi/Wtsi mice were obtained from the 
Infrafrontier-EMMA repository (strain number EM:10219). These mice carry a mutated 
allele where the function of the Nhlrc2 gene is inactivated by the insertion of a targeting 
cassette that contains the expression reporter beta galactosidase gene [27]. Heterozygous 
mice were cross-bred, pups were genotyped or pregnant females dissected and embryos 
analysed. The expression of Nhlrc2 in embryos was studied by staining for the expression 
of the lacZ reporter. On embryonic day 2.5 (E2.5), morulae were flushed from the uterus 
in accordance with a previously described protocol [19].
 
Embryos that were grown 
overnight in a microculture drop were transferred onto a gelatinised 24-well plate, each 
into its own well with 300 µl of embryonic stem cell medium, and left to grow for 10–12 
days, after which DNA was extracted, as described [23]. 
 
Generation of zebrafish morphants (Electronic Supplementary Material) 
Two morpholinos against zebrafish nhlrc2 (ENSDARG00000089581) were designed; the 
first morpholino was against the ATG-site to prevent translation and the second against the 
exon-intron boundary in the 3’ end of exon 4 (ENSDARE00000919598) to prevent 
splicing, which would both lead to a frameshift and premature termination of translation. 
The effect of the splice-site blocking morpholino for nhlrc2 levels was quantified using 
PCR. The knockdown efficiency was determined from an agarose gel using ImageJ v1.49 
by calculating the ratio of the wild-type (WT, the unmodified band) to the sum of all bands 
in a single lane (WT and two morpholino modified bands corresponding to exon exclusion 
and intron inclusion caused by splice site blocking).  
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Quantification of the affected cells in the midbrain region of zebrafish morphants 
from transmission electron micrographs 
From five zebrafish injected with random sequence control morpholino (5.1 ng) and five 
zebrafish injected with nhlrc2 splice site-blocking morpholino (5.0 ng), five random 
electron micrographs were taken from sagittal thin sections of the midbrain area. All the 
cells with visible nuclei and that were fully within the imaged area were counted and 
analysed for their integrity using iTEM software (Olympus Software Imaging Solutions 
GMBH). Cells with excess vacuolisation or disintegration were classified as affected.  
 
Statistics   
Differences were considered statistically significant (*) if the p value was 0.01– 0.05, very 
significant (**) if the p value was 0.001–0.01, and highly significant (***) if the p value 
was <0.001. A paired two-tailed student t-test was used to analyse the statistical 
significance. Zebrafish dechorionation timing differences were calculated with the log rank 
Mantel-Cox method, and values below 0.05 were considered significant. 
 
Results 
Clinical findings   
Family A. Two brothers were born after normal consecutive singleton pregnancies to 
healthy parents in this non-consanguineous Finnish family. Both siblings presented at 2 
months of age with feeding problems, muscular hypotonia, shoulder hypertonia and 
irritability. During the following months, both had delayed development, recurrent 
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infections, growth failure, respiratory problems and malabsorption. They subsequently 
developed dystonic tetraplegia, poor visual contact, progressive respiratory difficulties, 
transient liver dysfunction, and chronic haemolytic anaemia. The elder brother additionally 
presented with epileptic seizures and kidney dysfunction related to metabolic crisis at 9 
months. The disease course was progressive and, despite intensive care, both patients died 
(at 1 year 9 months and 1 year 1 month, respectively) of progressive respiratory failure.  
Family B. In this non-consanguineous Finnish family, the affected son was the first 
infant born to healthy parents. The mother had gestational hepatosis and toxaemia. At 2 
months, the infant presented with irritability, floppiness, haemolytic anaemia, feeding 
problems, frequent diarrhoea and poor weight gain. At 4 months, he was hospitalised 
because of a suspected seizure, poor general condition and respiratory problems. During 
the following months, he had delayed development, dystonia, failure to thrive, strabismus, 
recurrent infections, and respiratory difficulties. The disease course was progressive, and 
despite intensive care, the patient passed away at 1 year 2 months due to respiratory failure. 
All three patients appeared healthy at birth, but manifested at 2 months with unique 
multi-organ symptoms with a progressive disease course that resembled no known disease 
phenotype. Table 1 summarises the major clinical findings, including progressive 
cerebropulmonary symptoms, transient liver dysfunction, progressive growth failure and 
chronic haemolytic anaemia. Radiological investigations revealed over-inflated lungs with 
perihilar interstitial opacities, diffuse infiltrations and atelectasis (Online Resource Fig. 7) 
and thin corpus callosum (Online Resource Fig. 8). Additional findings included increased 
echogenicity of the kidneys (Patient 1) and hepatomegaly during metabolic crisis (Patients 
1 and 2), enlarged thymus (Patient 2) (Online Resource Fig. 9), dilated lateral ventricles, 
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frontal sulci resembling cerebral atrophy (Patients 2 and 3) and increased signal intensity 
of the globus pallidum (Patient 3) (Online Resource Fig. 8). Visual evoked potentials 
(VEPs) revealed increased latencies and giant responses, indicating dysfunction of the 
visual tract (Patient 1). Electroencephalographs (EEGs) showed slow background activity 
and frontal bilateral rhythmic high-amplitude sharp delta transients, indicating metabolic 
encephalopathy (Patient 1). The EEG of Patient 3 was normal at 5 months, but at 11 months 
it was monotonic during sleep and consisted of 4-Hz delta waves without normal sleep 
spindles and vertex waves. Detailed descriptions of the clinical manifestations are 
presented in the Electronic Supplementary Material.  
 
Histopathological findings in the brain 
Post mortem neuropathological examinations were performed for all three patients. The 
findings in Patient 1 included brain atrophy (942 g, reference 1050 g); thin corpus 
callosum; small hippocampal regions and increased angiomatosis-like leptomeningeal, 
cortical and superficial white matter venous and capillary vascularisation and congestion 
(Fig. 1a). Superficial vascular changes were observed macroscopically. Widespread 
cerebral cortical oedema, focal neuronal loss and gliosis were observed (Fig. 1b and c) 
Symmetrical vacuolar degeneration and myelin loss of the fibres at the level of the crus 
cerebri in the midbrain were detected, as well as vacuolar degeneration of the white matter 
of the cerebellum, cerebellar oedema, focal Purkinje cell depletion and gliosis (Fig. 1d). 
Neuronal depletion of the anterior horns of the spinal cord was also found.  
Patient 2 also had brain atrophy (764 g, reference 900 g), a thin corpus callosum and 
prominent congested leptomeningeal and superficial brain parenchymal vasculature. 
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Furthermore, the following neurodegenerative findings were detected: vacuolar 
degeneration and myelin loss of the corpus callosum and central white matter; vacuolar 
degeneration of the optic tract and the internal capsule; neuronal depletion of the corpora 
mammillaria, hypothalamic area and amygdaloid nucleus, as well as subthalamic and 
thalamic nuclei; vacuolar degeneration and myelin loss of the fibres of the crus cerebri and 
superior cerebellar peduncle and reticular formation in the midbrain, tegmentum and 
medial lemniscus in the pons (Fig. 1e-h). Other findings included mild vacuolar 
degeneration, myelin loss of the fibres of the pyramids and reticular formation in the 
medulla and in the white matter of the cerebellum. In addition, there was patchy neuronal 
loss in the anterior horns of the spinal cord.  
Examinations of samples from Patient 3 revealed brain atrophy (742 g, reference 860 
g), but a mostly normal corpus callosum, cerebral cortex and hippocampus. However, 
vascular congestion and angiectasia were detected. The temporal white matter exhibited 
vacuolar degeneration. Furthermore, the following findings were detected: vacuolar 
degeneration and neuronal depletion in the hypothalamic and amygdaloid nuclei and the 
putamen; vacuolar degeneration and myelin loss in the spinothalamic tract, medial 
lemniscus, superior cerebellar peduncle and reticular formation; degeneration of the 
anterior pontine nuclei; and minimal vacuolar degeneration in the white matter and dentate 
nucleus of the cerebellum.  
 
Histopathological findings in the lungs 
The lung biopsy samples from Patients 2 and 3 revealed no normal lung tissue; the lung 
tissue had been replaced by interstitial fibrosis resembling what is normally associated with 
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non-specific interstitial pneumonia (NSIP) (Fig. 2a and b). The alveolar epithelial cells 
appeared hyperplastic, and there were focal loose fibrotic areas positive after Alcian 
blue/periodic acid–Schiff (AB-PAS) staining. No hyaline membranes or diffuse alveolar 
damage (DAD) were visible.  
Autopsy samples of the lungs were available from all three patients, and all the 
samples showed varying amounts of interstitial changes and fibrosis (Fig. 2c-h). Interstitial 
fibrosis in the lungs of Patient 1 was milder than in the lungs of his younger brother (Patient 
2) (Fig. 2c). The lungs of Patient 2 revealed advanced interstitial fibrosis as a prominent 
feature, which was consistent with the findings in the lung biopsy samples; however, the 
degree of fibrosis in the autopsied lungs was more severe. In the lungs of Patient 3, the 
fibrosis was mainly moderate or mild. The general histological appearance of the autopsied 
lungs resembled that of NSIP. Intra-alveolar hyaline, hyaline membranes and squamous 
epithelial metaplasia reflecting DAD were intermittently observed in the lungs of Patients 
1 and 3 but not in Patient 2 (Fig. 2g). Novel histopathological structures that we have 
termed granuloma-like lesions were observed in all cases, but in varying numbers; multiple 
lesions in five lung tissue sections in Patient 1, hundreds of lesions in five lung tissue 
sections in Patient 2 and fewer than 10 lesions in eight lung tissue sections of Patient 3 
(Fig. 2c, e and h). Hyaline-resembling fibrotic areas were observed around the arteries in 
all cases, but the walls of the vessels were otherwise normal (Fig. 2d and e). Some airways 
were dilated, but no true honeycombing was found.  
Most of the granuloma-like lesions were surrounded by hyaline-resembling 
extracellular material that contained large spindle-shaped cells. These large spindle-shaped 
cells were positive for alpha-smooth muscle actin (α-SMA) (myofibroblast marker) and 
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negative for cytokeratin (epithelial cell marker), phosphoglucomutase 1 (PGM1) 
(macrophage marker), smooth muscle myosin heavy chain (SMMHC) (smooth muscle cell 
marker) and caldesmon (smooth muscle cell marker) (Fig. 2f). The immunohistochemical 
phenotype indicated that the cells in the granuloma-like lesions were myofibroblasts.  
 
Histopathological findings in the other organs 
All three patients had hepatomegaly (435–485 g, reference weight 330–370 g). An autopsy 
liver sample from Patient 1 showed widespread microvesicular steatosis and foci of 
hepatocellular necrosis. Patient 1 also had cardiomegaly (90 g, reference weight 56 g) with 
slightly increased connective tissue. Autopsy revealed mild muscular atrophy in Patients 1 
and 2; previous muscle biopsy samples from these patients revealed no histopathological 
changes. Furthermore, upon histological examination, the autopsy revealed atrophic 
thymus and adrenal glands without any specific abnormalities. 
 
Electron microscopic findings in the lungs and liver 
We analysed lung and liver autopsy samples from Patient 2 using a transmission EM 
(TEM). In the lungs, the most abundant cell types were myofibroblasts and smooth muscle 
and alveolar epithelial cells (Fig. 3a-c). Alveolar epithelial cells were mostly type II cells 
with intracellular lamellar bodies; only a few type 1 alveolar cells were detected (Fig. 3a 
and b). In the liver tissue samples, we observed steatosis (Fig. 3d) and collagen 
accumulation both inside- and outside of the hepatocytes, and a basement membrane was 
evident in the space of Disse (Fig. 3e and f).  
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Variants of NHLRC2 in the two families 
WES revealed compound heterozygous variants in NHLRC2, which encodes for the poorly 
characterised NHL repeat containing protein 2 in all three of the affected children (Fig. 4a). 
The NHLRC2 gene is located in chromosome 10: 113,854,661-113,917,194 and the protein 
contains an N-terminal thioredoxin-like domain together with six NHL amino acid 
sequence repeats (named after three original genes NCL-1, HT2A and LIN-41) (Fig. 4b) 
[24]. Previously, mutations in NHLRC2 have not been associated with any other human 
disease. The FINCA patients carried the heterozygous variant NM_198514:c.442G>T, 
which led to amino acid substitution p.Asp148Tyr in exon 3 within the highly conserved 
thioredoxin-like domain (Fig. 4b and d, Online resource Fig. 10). However, in the classical 
insulin-reduction activity assay for thioredoxins, neither full-length NHLRC2 nor the 
isolated thioredoxin-like domain produced in E. coli showed significant thioredoxin 
activity (Fig. 4c).   
In addition, all three patients had a heterozygous frameshift 2-bp deletion 
NM_198514:c.601_602delAG, which caused p.Arg201GlyfsTer6 in exon 3 (Fig. 4a and b, 
Online Resource Fig. 10). Both the variants were segregated from their healthy parents. 
Genealogies of the patients, traced back seven to nine generations to the 1750s, revealed 
that the two families did not have common ancestors. We were unable to confirm the 
consanguinity of these two core families; their ancestors were born in northern Finland at 
least 150 miles apart.  
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Allele frequency of NHLRC2 variants among populations 
We did not detect p.Asp148Tyr or p.Arg201GlyfsTer6 variants in the northern Finnish 
cohort of infants (n=306). In the Finnish population represented by Sequencing Initiative 
Suomi (SISu) data (n=10,488), p.Asp148Tyr (rs201701259) was rare, with a frequency of 
0.003. In SISu, a frequency of 0.0001 was reported for p.Arg201GlyfsTer6 (rs757267294); 
however, the variant had not passed through quality control. In the Exome Aggregation 
Consortium (ExAc) data, the p.Asp148Tyr variant was present in non-Finnish European 
(n=33,351), South Asian (n=8,252), and African (n=5,202) populations with frequencies 
of 0.0003, 0.0002 and 0.0001, respectively. The p.Arg201GlyfsTer6 variant had a 
frequency of 0.0001 in non-Finnish Europeans (n=33,239) and was absent from other 
populations. The two variants were not detected as homozygous occurrences in any of the 
populations.  
 According to the SISu data, at least one of the two NHLRC2 variants, p.Asp148Tyr 
(rs201701259), was enriched in the Finnish population (n=10,488; natural logarithm of 
odds ratio 1.97), indicating that occurrence of the two variants in a compound heterozygous 
state in the two core families may be, at least partly, explained by their enrichment in the 
Finnish population.  
 
Expression of Human NHLRC2  
We investigated mRNA expression of variants NM_198514:c. 442G>T and 
c.601_602delAG in the patients’ fibroblasts. NHLRC2 mRNA expressed only the 
c.442G>T missense variant and not c.601_602delAG, confirming the origin of the variants 
from separate alleles and the degradation of mRNA with the frameshift 2-bp deletion 
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(Online Resource Fig. 10). The relative quantity of NHLRC2 expression was studied by 
qPCR and showed approximately a two-fold decrease in patient-derived, immortalised 
fibroblasts compared to the controls (Fig. 4e).  
The protein expression of NHLRC2 with the p.Asp148Tyr variant was investigated 
in the immortalised fibroblasts derived from patients and healthy controls. Immunoblotting 
revealed approximately a ten-fold decrease in the levels of NHLRC2 in whole-cell extracts 
from patients compared to control fibroblasts (Fig. 4f and g), further indicating the non-
neutral role of the NHLRC2 variants.  
Immunoblotting was also performed to investigate the expression of NHLRC2 in 
tissue homogenates from control autopsy samples (kidney, heart, muscle, liver, lung and 
brain tissue). NHLRC2 was detected in all human tissues included in the study (Online 
Resource Fig. 11). According to three public RNA expression databases (mouse) Brain 
RNA-Seq (https://web.stanford.edu/group/ barres_lab/brain_rnaseq.html) [32], Human 
Brain Transcriptome (http://hbatlas.org/) and the Atlas of the Developing Human Brain 
(www.brainspan.org)[13] the expression of mouse Nhlrc2 is highest in astrocytes, 
oligodendrocyte progenitor cells, newly formed oligodendrocytes and endothelial cells. 
Mouse Nhlrc2 is also expressed in neurons, myelinating oligodendrocytes and microglia. 
According to the Atlas of the Developing Human Brain (www.brainspan.org)[17], 
expression of human NHLRC2 was highest in foetal brains during early pregnancy. The 
average expression levels of human NHLRC2 are similar among the cerebellar cortex, 
mediodorsal nucleus of the thalamus, striatum, amygdala, hippocampus and 11 areas of the 
neocortex (Online Resource Fig. 12). 
 
19 
 
Nhlrc2tm1a knockout mice 
Nhlrc2 knockout (KO) mice (21 litters, n=154) were genotyped from heterozygous 
breeding pairs (Table 2). The ratio of born mice between WT and heterozygous mice was 
1:2.125, which is in line with Mendelian segregation. The heterozygous mice, both female 
and male, were vital and bred well, indicating normal function of Nhlrc2tm1a KO gametes. 
We also genotyped 53 embryos from six heterozygous breeding pairs on E10.5 and isolated 
and genotyped 45 morulae (E2.5) from six heterozygous breeding pairs (Online Resource 
Fig. 13). We did not detect any homozygous Nhlrc2 KO mice, embryos or morulae, 
indicating that the lethality of Nhlrc2tm1a KO homozygotes occurs between the fertilisation 
and morula (E2.5) stage. Nhlrc2 expression analysis with LacZ-reporter mice indicated 
widespread expression throughout the body while WT littermates remained negative (Fig. 
5). RNA in situ data of the Eurexpress atlas (www.eurexpress.org/ee/) showed strongest 
Nhlrc2 expression in the brain, the central nervous system, the alimentary system and in 
the cardiovascular system of mouse embryos (E14.5) [4].  
 
Zebrafish knockdown and dechorionation 
We then decided to study the role of nhlrc2 in early embryogenesis using zebrafish, which 
is a convenient model organism for developmental studies because of the transparency of 
the embryos. The morphogenesis of the primary organ systems of a zebrafish is complete 
in 48 hours and the larvae display food seeking and avoidance behaviour 72 hours after 
conception [12]. First, we assessed the efficacy of nhlrc2 splice site-blocking morpholino 
with PCR. As predicted, morphants had altered mRNA splicing compared to the untreated 
controls. The effect gradually faded toward 4 dpf (Online Resource Fig. 14). Besides minor 
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swelling in the abdomen, nhlrc2 morphants developed normally (Online Resource Fig. 14) 
without any apparent developmental defects. Both splice site-blocking morpholino (3.6 ng) 
and translation-blocking morpholino (2.3 ng) were used, with both co-injected with an 
equal amount of p53 morpholino [21]. A slight delay was observed in the timing of the 
dechorionation (Online Resource Fig. 15a), but a similar effect was also observed in the 
random controls (Online Resource Fig. 15b), suggesting both were non-specific effects. 
Because there were no apparent changes in the gross morphology of developing 
nhlrc2 morphants, we next investigated the central nervous system in more detail using 
TEM. Because we were not able to ascertain the effect of the translation-blocking 
morpholinos without a validated antibody, we chose to use the splice site-blocking 
morpholinos for the TEM analysis. In this experiment, we achieved approximately 95.2% 
knock-down efficiency at the time point of 2 dpf by using the splice site-blocking nhlrc2 
morpholino (5.0 ng) (Online Resource Fig. 16). Using TEM, the quantitative analysis of 
the midbrain region from the 2 dpf morphants showed statistically significant increments 
in the number of affected cells in nhlrc2 knock-downs compared to the controls injected 
with a random sequence morpholino (Fig. 6). The data indicate that nhlrc2 has a key role 
in maintaining the cellular integrity of the central nervous system in developing zebrafish 
embryos.  
 
Discussion 
Based on clinical and molecular genetic data we have identified a novel cerebropulmonary 
and multi-organ disease, which we have named FINCA. This disease is characterised by a 
unique combination of tissue fibrosis, neurodegeneration and cerebral angiomatosis. Using 
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WES we identified identical compound heterozygous NHLRC2 variants in three affected 
children from two unrelated families. In addition, we used a KO mouse model and zebrafish 
morphants to investigate the consequences of absent or decreased Nhlrc2 expression; 
finally, we performed biochemical studies on human recombinant NHLRC2.  
NHLRC2 is conserved in eukaryotes, having 84% sequence identity between human 
and mouse orthologues. The function of NHLRC2 is currently unknown. There are two 
NHLRC2 transcript variants in humans, both containing six NHL repeats that may form 
part of a TolB-like six-bladed beta-propeller. Six-bladed beta-propellers occur in a wide 
range of proteins, including 165 human proteins listed in InterPro [18]. They are often 
involved in protein–protein interactions. The longer isoform of NHLRC2 also has an N-
terminal thioredoxin-like domain with an unusual motif (CCINC), where the active site of 
thioredoxin (WCGPC for human thioredoxins 1 and 2) is usually located. Interestingly, the 
missense variant identified from the patients in this study located in the thioredoxin-like 
domain and led, together with the frameshift variant, to significantly reduced expression of 
NHLRC2 at the mRNA and protein level in patient-derived fibroblasts. A classical insulin-
reduction activity assay for thioredoxins revealed that neither full-length NHLRC2 nor the 
isolated thioredoxin-like domain showed significant thioredoxin activity. This may be 
because of the substrate specificity of NHLRC2, which could be mediated by protein–
protein interactions involving the six-bladed beta-propeller. Thus, insulin may be excluded 
from the active site; however, the thioredoxin fold motif is versatile, with both redox [16] 
and non-redox functions. An example of a non-redox function occurs in SasA, a circadian 
clock-associated histidine kinase [29]. This versatility plus the unusual motif in place of 
the active site indicates that the N-terminal domain has a thioredoxin fold, but no 
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thioredoxin activity. Conservation of the active-site cysteines indicates that the protein 
either has or regulates a redox-related function.  
Based on large population cohort datasets, the rare variants identified in our patients 
are not restricted to the Finnish population; they are also present as simple heterozygotes 
in other populations. Our genotyping analysis of Nhlrc2 KO mice, foetuses and morulae 
revealed that homozygosity was lethal whereas heterozygous mice were viable and non-
symptomatic. Interestingly, the nhlrc2 morphant zebrafish embryos had a significant 
number of affected cells in the midbrain, indicating that nhlrc2 has an important role in the 
maintenance of cell survival in the developing brain. In contrast to the postnatal onset of 
the symptoms in humans, the timing of the effects of the zebrafish knockdown suggests the 
morphant zebrafish model does not fully reflect the features of the human disease. We are 
currently working on generating a knockout zebrafish model to better observe the potential 
symptoms at later stages of development.  
Autopsy studies revealed that in FINCA patients, there was increased angiomatosis-
like leptomeningeal, cortical and superficial white matter vascularisation and congestion, 
in addition to white matter degeneration and variable neuronal degeneration. According to 
currently available RNA expression data in Human Brain Transcriptome 
(http://hbatlas.org/), the average expression level of human NHLRC2 is similar among 
different regions of the human brain. The expression of mouse Nhlrc2 is the highest in 
astrocytes, oligodendrocyte progenitor cells, newly formed oligodendrocytes and in the 
endothelial cells [32]. Altogether, this expression data indicate that NHLRC2 is widely 
expressed in the different regions and cell types of the brain. However, based on the current 
knowledge on the function of NHLRC2 it is difficult to conclude the primary mechanism 
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behind FINCA disease and to exclude the role of secondary processes such as ischemia as 
a cause of certain neuropathological findings described in our patients such as depletion of 
Purkinje cells and pyramidal neurons in Ammon’s horn. Lung biopsy and autopsy studies 
showed severe interstitial fibrosis and previously undescribed granuloma-like lesions. The 
granuloma-like lesions were enriched with myofibroblasts that accumulate in areas 
surrounding granulomas in several granulomatous lung diseases such as sarcoidosis, 
atypical mycobacteriosis and tuberculosis [9]. The predominance of type II alveolar cells 
and paucity of type I cells were evident. Lung autopsy specimens additionally revealed 
DAD. Furthermore, all the patients had hepatomegaly. Liver samples for TEM were 
available only from one patient (Patient 2) revealing steatosis and accumulation of collagen  
bundles.   
From the previous literature, we have found only one other “FINCA-like” 
cerebropulmonary disease called brain–lung–thyroid syndrome (BLT syndrome, OMIM 
118700) or choreoathetosis and congenital hypothyroidism with or without pulmonary 
dysfunction (CAHTP, MIM #610978) that begins with muscular hypotonia followed by 
choreoathetosis, dystonia, ataxia, and dysarthria. This is an autosomal dominant infantile-
onset disorder caused by mutations in thyroid transcription factor 1 (NKX2-1/TITF1; 
14q13.3) [3,28]. The phenotype is less severe than in FINCA and varies between and within 
families; some patients show neonatal respiratory distress syndrome (RDS), developmental 
delay, symptoms of possible hypothalamic dysfunction or congenital cardiac septal defects 
[28]. Neuroimaging in some NKX2-1 related cases has shown structural brain 
abnormalities including agenesis of the corpus callosum [20], and autopsies have revealed 
reduced numbers of striatal and neocortical interneurons consistent with a defect in 
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neuronal migration [13]. In addition to RDS in neonates, pulmonary disease may present 
with interstitial lung disease in young children, and pulmonary fibrosis in older persons 
[20]. Histologic studies on patients with NKX2-1 related pulmonary dysfunction have 
identified interstitial widening and pneumocyte hyperplasia, desquamative interstitial 
pneumonia, accumulation of foamy alveolar macrophages, and pulmonary alveolar 
proteinosis [6]. The risk for pulmonary carcinoma is increased in young adults with 
an NKX2-1 related disorder.  In BLT syndrome, thyroid involvement may present as 
subclinical hypothyroidism with mildly elevated thyroid stimulating hormone (TSH) or 
hyperthyrotropinemia. Additional symptoms, including failure to thrive, malabsorption, 
and intellectual deficit, have been reported in patients with deletions on chromosome 14, 
including NKX2-1 (www.orpha.net). In FINCA disease, in addition to cerebropulmonary 
symptoms, we also observed failure to thrive, malabsorption, early-onset chronic 
haemolytic anaemia, and recurrent infections in all three patients. Furthermore, transient 
liver dysfunction (Patients 1 and 2), transient kidney dysfunction (Patient 1), subclinical 
hypothyroidism (Patient 3, Electronic Supplementary Material), a transient increase in 
serum tumour markers and a non-specific decrease in the oxidative activity of monocytes 
(Patient 2, Electronic Supplementary Material) were noted.  
Our studies indicate that NHLRC2 has a significant role in the CNS. However, 
further research is required to define the complex role of NHLRC2 in the pathogenesis of 
FINCA disease and, more commonly, its role in tissue fibrosis, neurodegeneration and 
cerebral angiomatosis. The presentation of FINCA disease and potentially other diseases 
may vary in response to the genetic defect in NHLRC2, environmental factors and other 
genetic factors. Recently, NHLRC2 has been listed as one of six novel blood-based 
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biomarkers for Alzheimer´s disease, indicating its yet undefined role in neurodegeneration 
[15]. Our expression analysis with LacZ-reporter mice indicates widespread expression of 
Nhlrc2 throughout the mouse embryo. This, in connection with the severe multi-organ 
phenotype of FINCA patients, indicates that NHLRC2 has a vital role in early 
embryogenesis and in maintenance of multi-organ homeostasis after birth. We propose that 
NHLRC2 variants should be considered in patients with phenotypes that present as a 
combination of neurological and respiratory symptoms or additional multi-organ 
manifestations.  
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Figure captions 
Fig. 1 Histopathological findings in brain autopsy samples from patients with NHLRC2 
variants. a Autopsy findings from Patient 1 revealed increased angiomatosis-like 
leptomeningeal vascularisation. b Degeneration and depletion of the pyramidal cells of the 
hippocampus. c Higher magnification of the Ammon’s horn showing gradual depletion of 
pyramidal neurons. d Purkinje cells of the cerebellum (between arrowheads). e-h Patient 2 
had vacuolar degeneration and myelin depletion in the pons. Haematoxylin and eosin stain 
(a-f) and luxol fast blue stain (g, h). The images were taken with an Aperio AT2 digital 
pathology slide scanner (Leica Biosystems, Wetzlar, Germany). Scale bars: 200 µm  
 
Fig. 2 Histological findings in lung samples from patients with NHLRC2 variants. a, b 
Interstitial fibrosis was present in the lung biopsy samples. c, e, f, h Granuloma-like lesions 
(arrows) within regions with variable amounts of necrosis (stars) were present in the 
autopsy samples from each patient. d Perivascular fibrosis was visible around the artery 
(arrowhead). f Spindle-shaped cells in a granuloma-like lesion were positive for alpha–
smooth muscle actin (short arrows). g Hyaline membranes (short arrows) were present in 
the alveoli. a, b Lung samples collected by lung biopsy (a, b) and during autopsy (c-h). 
Samples from Patient 1 (c), Patient 2 (a, d-f) and from Patient 3 (b, g, h). Haematoxylin 
and eosin stain (a-e, g). Scale bars: 80 µm 
 
Fig. 3 Electron microscopy analysis of lung (a-c) and liver (d-f) autopsy samples. a Lung 
alveoli contained type II pneumocytes (P) and the alveolar space was very limited (L, the 
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lumen of the alveolus). b In addition to type II pneumocytes (P), myofibroblasts (M) were 
present with diverging ‘limb-like’ projections. c Myofibroblasts with ultrastructural 
features such as abundant endoplasmic reticulum (E) and adherens junctions (A) had 
produced fibrotic extracellular collagen bundles (C). d The liver had many large fat (F) 
vacuoles in the hepatocytes. e Thin and fragmentary basement membrane (B) was detected 
in the space of Disse adjacent to the endothelial cells surrounding the sinusoidal lumen (L). 
f The accumulation of fat vacuoles (F) and collagen bundles (C) in hepatocytes. Sinusoidal 
lumen (L). Scale bars: 10 µm (a, d), 5 µm (b), 2 µm (c, e, f) 
 
Fig. 4 Variants p.Asp148Tyr and p.Arg201GlyfsTer6 in NHLRC2 in patients with FINCA 
disease from two non-consanguineous families. a Pedigrees and the segregation of 
heterozygous variants p.Asp148Tyr and p.Arg201GlyfsTer6 in Families A and B. The 
probands of the families are indicated with an arrow and the healthy siblings of the patients 
are indicated with empty symbols. b The structural domains of NHLRC2 and location of 
the variants. c Neither full-length NHLRC2 (NHLRC2-FL) nor the isolated thioredoxin-
like domain (NHLRC2-trx) produced in E. coli showed significant thioredoxin activity in 
the insulin reduction assay. d Conservation of the thioredoxin-like domain region 
containing p.Asp148Tyr (p.D148Y) in red [5]. e QPCR showed a highly significant 
decrease in the relative quantity of NHLRC2 mRNA in patient-derived fibroblasts 
compared to controls according to a two-tailed student t-test. f Immunoblotting indicated a 
significant loss of the p.Asp148Tyr NHLRC2 protein in fibroblasts from Patients 1–3 
compared to the levels of GAPDH. g Immunoblotting data presented as numerical values 
measured using Image J and statistical analysis by a two-tailed student t-test. 
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Abbreviations: D148Y, p.Asp148Tyr; R201GfsX6, p.Arg201GlyfsTer6; Trx, thioredoxin; 
C, control; P, patient; FL, full length. Differences were considered as statistically 
significant (*), with p value 0.01-0.05 and highly significant (***) with p -value < 0.001 
 
Fig. 5 LacZ mouse tissue staining. Heterozygote Nhlrc2tm1a mice had a strong β-
galactosidase signal throughout the body. Heart and thymus (a); Lungs (b); Kidneys, 
adrenal glands and gonads (c); Liver (d) and Brain (e, f) (e WT; f heterozygote Nhlrc2tm1a 
mice). WT littermates were negative for β-galactosidase signal   
 
 
Fig. 6 Transmission electron microscopy image from the midbrain region of the 2-dpf-
zebrafish morphant. a A cross section of a zebrafish embryo at 2 dpf with a circled area 
specifying the exact location from which the electron micrographs were taken. b Cells with 
excess vacuolisation or disintegration were classified as affected (marked with an asterisk 
in Fig. 6d). In the midbrain 5.8 % of the 810 cells analysed were affected by the nhlrc2 
splice site-blocking morpholinos, whereas only 1% of the 850 cells were affected in MO 
controls. c Midbrain of the random sequence morpholino injected control. d Midbrain of 
the nhlrc2 splice site-blocking morphant. Abbreviations: SB, splice site-blocking; MO, 
morpholino. Differences were considered as statistically very significant (**) with p value 
0.001-0.01  
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Electronic supplementary material  
Fig. 7 Radiological findings of chest X-rays and high-resolution computed tomography of 
Patients 1–3. a Patient 1 at 7 months of age shows flattened hemidiaphragms and 
hyperlucent lungs demonstrating over-inflated lungs, small air-filled bullae of the right 
mediobasal lung (short arrows) and perihilar small atelectasis (long arrow). Performed 
during an acute metabolic crisis at the age of 9 months, the chest X-ray demonstrates 
perihilar and basal airspace opacities and axial HRCT confirms bilateral consolidations 
(long arrows) and reticular opacities (short arrows). b Patient 2 at 4 months of age 
demonstrates mediastinal and hilar prominence (short arrows), over-inflated lungs, and 
diffuse reticular interstitial opacities. At 4 months of age, HRCT reveals widespread 
bilateral ground-glass opacities (short arrow), interstitial infiltrations (long arrows) and 
atelectasis (black arrowhead), mildly enlarged thymus (white arrowhead) and left hilar 
adenopathy (asterisk). At 1 year of age, chest X-rays show the progression of interstitial 
infiltrations and bilateral dense consolidations (long arrows). c Patient 3 at 4 months of age 
reveals over-inflated lungs and bilateral perihilar interstitial opacities (short arrows). At 13 
months of age, the chest X-ray shows diffuse infiltrations with reticulation. HRCT confirms 
diffuse bilateral ground-glass opacification, peripheral interstitial septal thickening and 
lobular pleural thickening (long arrows) 
 
Fig. 8 Findings from brain magnetic resonance imaging of Patients 1–3. a Sagittal T1-
weighted magnetic resonance imaging (MRI) shows the thin corpus callosum of Patient 1 
at 7 months of age. b Patient 2 at 10 months of age. c Patient 3 at 10 months of age (short 
arrows). The axial T2-weighted and coronal T1-weighted MRIs of Patients 2 (b) and 3 (c) 
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demonstrate slightly dilated lateral ventricles and cortical sulci. c Increased signal intensity 
of the globus pallidus on the axial T2-weighted MRI of Patient 3 (arrowheads) 
 
Fig. 9 Findings from abdominal ultrasound and magnetic resonance imaging of internal 
organs and thymus of Patients 1 and 2. a The abdominal ultrasound findings (Patient 1 at 
10 months of age) show increased cortical echogenity with the strand-like hypoechogenic 
outerzone of both kidneys (short arrows). b The abdominal T2-weighted axial MRI of 
Patient 2 at 4 months of age shows hepatomegaly and a non-expansive hypointense lesion 
of the right liver lobe (long arrows). c The lesion is also hypointense on the T1-weighted 
coronal MRI (long arrows). d The axial fat saturation T1-weighted MRI of Patient 2 shows 
that the lesion (arrowheads) in the liver is less enhanced by the gadolinium contrast agent 
than the rest of the liver. e Normal echogenity of the right liver lobe of Patient 2 at the age 
of 4 months. f A slightly enlarged thymus of Patient 2, which was seen in the coronal T1-
weighted MRI (asterisk) 
 
Fig. 10 a Electropherograms showing both heterozygote NM_198514:c.442G>T and 
c.601_602delAG variants in genomic DNA from the patient. b The RNA extracted from 
the patients’ fibroblasts has only c.442G>T. Thus, Sanger sequencing of mRNA confirms 
that the variants reside in separate haplotypes and have been inherited as compound 
heterozygotes in all patients. Furthermore, the absence of the c.601_602delAG variant 
indicates that the transcript with the frameshift deletion is processed through nonsense 
mediated RNA decay  
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Fig. 11 Immunoblotting to detect NHLRC2 protein expression in human tissue 
homogenates from control autopsy samples. NHLRC2 was detected in all studied human 
organs including the heart (He), kidney (Ki), muscle (Mu), liver (Li), lung (Lu) and brain 
(Br). GAPDH was used as a loading control 
 
Fig. 12 Nhlrc2 is expressed in various cell types of the mouse brain and NHLRC2 
expression is highest in the early human life.  a An RNA-Seq transcriptome and splicing 
database of the glia, neurons and vascular cells of the cerebral cortex show the highest 
Nhlrc2 expression in astrocytes, oligodendrocyte progenitor cells, newly formed 
oligodendrocytes and endothelial cells. Nhlrc2 was also expressed in neurons, myelinating 
oligodendrocytes and microglia. (OPG) oligodendrocyte progenitor cells [32]. 
Abbreviations: FPKM, fragments per kilobase per million. b The average expression levels 
of NHLRC2 are similar between the cerebellar cortex (CBC), mediodorsal nucleus of the 
thalamus (MD), striatum (STR), amygdala (AMY), hippocampus (HIP) and 11 areas of the 
neocortex (NCX) in the human brain (http://hbatlas.org/). c The expression is highest in the 
early development of the human brain. The number of samples is indicated on the top of 
the x-axis. Data from www.brainspan.org [17]. Abbreviations: RPKM, reads per kilobase 
per million; pcw, post conception week; mos, months; yrs, years 
 
Fig. 13 Wild-type (WT) and heterozygous (het) Nhlrc2 KO morulae and their growth in 
vitro. The morulae were isolated at embryonic day (E) 2.5 and co-cultured in a micro drop 
culture overnight. On the next day, the E3.5 compacted morulae and early blastocysts were 
transferred to separate gelatinised wells. At E4.5, the embryos had matured to the blastocyst 
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stage and at E5.5 they hatched and attached to the bottom of the plate. Cells were grown 
for several days to detect possible phenotypes and to obtain enough material for genotyping 
(E7.5, E10.5 and E13.5). No homozygous morulae were detected  
 
Fig. 14 nhlrc2 splice site-blocking morpholino alters the mRNA spicing in zebrafish 
embryos but not the gross morphology of the embryos. Indicated amount of splice site 
targeting morpholino (together with an equal amount of p53 morpholino) was injected into 
the yolk sacs of fertilised eggs at the 1-2 cell stage. a Arrows on the left show the expected 
product sizes after the splice site-blocking events (334 bp intron inclusion, 198 bp WT 
product, 76 bp exon exclusion), and below the image are indicated the times of RNA 
extraction as days post fertilisation (dpf). b Un-injected controls on the left, nhlrc2 splice 
site-blocking morpholino (3.6 ng) treated morphants in the middle and nhlrc2 translation-
blocking morpholino (2.3 ng) treated morphants on the right. The embryos appear to have 
WT morphology; only minor swelling was observed in the abdominal area in some 
individuals in both morphant groups at 3 dpf. However, this swelling diminished by 4 dpf. 
The images were taken with Axiovision software version 4.8 using a Zeiss SteREO Lumar 
V12 fluorescence microscope, equipped with 1.5X camera (Carl Zeiss MicroImaging 
GmbH, Göttingen, Germany) 
 
Fig. 15 The timing of dechorionation of the nhlrc2 morphants. The fraction of 
dechorionated embryos was recorded for selected hours post fertilisation (hpf). The 
significances were calculated with a log rank Mantel-Cox test. PBS control N=91, 
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untreated control N=47; p53 MO control N=23; untreated control N=36; random control 
MO 3.6 ng N=63; untreated control N=34 and splice site-blocking MO 3.6 ng N= 76, 
untreated control N=34. Graphs were generated with GraphPadPrism 5 
 
Fig. 16 Knockdown of nhlrc2 using splice site-blocking morpholino (nhlrc2 SB MO), 
translation-blocking morpholino (nhlrc2 TB MO), a combination (nhlrc2 SB+TB MO) of 
the two morpholinos compared to un-injected controls (Control) and random control 
morpholino (RC MO). a nhlrc2 splice site blocking morpholino alters the mRNA splicing 
in zebrafish embryos. The indicated amount of splice site-targeting morpholino (together 
with an equal amount of p53 morpholino) was injected into the yolk sacs of fertilised eggs 
at the 1-2 cell stage. After the indicated time, RNA was isolated, PCR was performed and 
PCR product was run on 2% agarose gel. Arrows on the left annotate the expected product 
sizes after the splice site-blocking events (334 bp intron inclusion, 198 bp WT product, 76 
bp exon exclusion), and below the image are the times of RNA extraction as days post 
fertilisation (dpf). b Knockdown efficiencies were calculated using ImageJ 1.49v. The 
levels of WT transcript are displayed above the bars for samples containing splice site-
blocking morpholinos 
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Case reports  
Family A 
Patient 1. Patient 1 was born at 38 weeks after a normal pregnancy and delivery to healthy, 
unrelated parents. The apgar score was 10/10, birth weight 3690 g, birth height 49 cm and 
head circumference 35 cm. He manifested with muscular hypotonia, dystonia and 
irritability at 2 months of age. He had delayed development and increased respiratory rate 
at the age of 3 months and alternating strabismus and loose faeces with transient diarrhoea 
at the age of 4 months.  
When the patient was clinically examined at the age of 7 months, he was found to 
have dystonic tetraplegia, increased deep tendon reflexes, increased respiratory rate (48 
breaths/min) with a bell-shaped chest but normal breath sounds and normal oxygen 
saturation values (SaO2) and poor visual contact. He also presented with unexpected 
unconsciousness and epileptic seizures. Laboratory investigations revealed haemolytic 
anaemia with decreased blood haemoglobin (75–92 g/l, reference 100–136 g/l) and blood 
haematocrit (0.21–0.26, reference 0.31–0.42), reticulocytosis (3.90–4.93%, reference 0.8–
2.0%), increased plasma lactate dehydrogenase (1048–1698 U/l, reference 135–375 U/l) 
and plasma haemoglobin (129–414 mg/l, reference 0.29–2.00 g/l). The Coombs test was 
negative. Blood cell morphology analysis revealed anisocytosis, macrocytosis, 
poikilocytosis, polychromasia, hypochromia, microcytosis, ovalocytes and red cell 
fragments. Ophthalmological investigation revealed decreased vision in both eyes (Teller 
visus 20/800/1200 and 20/600/800, respectively).  
From the age of 6 months, the child had breathing difficulties and recurrent 
respiratory and gastrointestinal symptoms but had negative screening results for common 
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viruses. Chest X-rays and high-resolution computed tomography (HRCT) at 7 months of 
age showed flattened hemidiaphragms and hyperlucent lungs, demonstrating over-inflated 
lungs, small air-filled bullae in the right mediobasal lung and perihilar small atelectasis 
(Fig. 7a).  
During an acute metabolic crisis at the age of 9 months, a chest X-ray showed 
perihilar and basal airspace opacities and axial HRCT confirmed bilateral consolidations 
and reticular opacities (Fig. 7a). The patient’s metabolic crisis included acute liver 
dysfunction with icterus and renal failure at the age of 9 months, which was triggered by 
viral gastroenteritis. During the subsequent 3-month period, he presented with 
hepatomegaly, increased liver transaminases and bilirubin, as well as icteric sclerae and 
skin. Extensive metabolic screening was negative, except for the following abnormal liver 
and kidney function tests taken during the acute metabolic crisis: increased plasma aspartyl 
aminotransferase (152–218 U/l, reference 10–50 U/l) and alanine aminotransferase (84–86 
U/l, reference 10–50 U/l), slightly increased serum bilirubin (51–92 µmol/l, reference ≤25 
µmol/l), conjugated bilirubin (62 µmol/l, reference ≤5 µmol/l), increased plasma gamma-
glutamyltransferase (124–147 U/l, reference 5–80 U/l) and plasma ammonia (NH4) (90–
110 μmol/l, reference <80 μmol/l), decreased serum prealbumin (0.09–0.15 g/l, reference 
0.24–0.42 g/l) and plasma albumin (27 g/l, reference 36–45 g/l), and increased plasma 
creatine (111–139 μmol/l, reference 15–35 μmol/l) and plasma urea (14.9–27.5 mmol/l, 
reference 1.7–8.3 mmol/l). Beta-hydroxybutyric acid and octandioic acid were present in 
urine during the metabolic crisis.  
An abdominal ultrasound revealed hepatomegaly and increased cortical echogenity 
with a strand-like hypoechogenic outer zone in the kidneys (Fig. 9a). A nasogastric tube 
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was implanted when the boy was 1 year old due to feeding problems, poor weight gain and 
progressive growth retardation (retardation of growth from 0 standard deviations [SD] to -
2 SD by the age of 7 months, decrease in relative weight from +12% to -20% and decrease 
in head circumference from -0.5 SD to -1.2 SD).  
Brain magnetic resonance imaging (MRI) at the age of 7 months revealed a thin 
corpus callosum (Fig. 8a). Brain auditory evoked potentials and electroretinogram were 
normal, but visual evoked potentials showed increased latencies and giant responses that 
resembled the findings of a muscle–eye–brain (MEB) disease and late-infantile neuronal 
ceroid lipofuscinosis (Jansky–Bielschowsky). Therefore, a rectal biopsy was also 
performed but did not reveal any vacuolar cells. Electroencephalogram (EEG) revealed 
slow background activity and frontal bilateral rhythmic high-amplitude sharp delta 
transients, indicating metabolic encephalopathy.  
A second episode of acute liver dysfunction at the age of 1 year 8 months was 
triggered by viral gastroenteritis and fever. The disease course was progressive, and the 
patient died at the age of 1 year 9 months due to respiratory failure.  
Patient 2. Patient 2 was the younger brother of Patient 1. He was born at 38 + 6 weeks with 
an Apgar score of 9/9, birth weight 3280 g, height 51 cm and head circumference 34.5 cm. 
Similar to his older brother, feeding problems and tachypnoea were noticed at the age of 2 
months.  
At the age of 4 months, the infant manifested with right-sided chest prominence, a 
relative weight of -32% and muscular hypotonia. In contrast to his older brother, the infant 
was able to make eye contact and responded with a smile. However, during the follow-up, 
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he presented with poor weight gain, developmental delay and gastrointestinal symptoms 
(diarrhoea) by the age of 5 months. At that time, breath sounds and SaO2 were normal.  
A chest X-ray at 4 months demonstrated mediastinal and hilar prominence, over-
inflated lungs and diffuse reticular interstitial opacities (Fig. 7b). Also at 4 months, HRCT 
revealed widespread bilateral ground-glass opacities, interstitial infiltrations and 
atelectasis, mildly enlarged thymus, and left hilar adenopathy (Fig. 7b and 9f). A brain 
MRI at 10 months of age showed a thin corpus callosum and slightly dilated lateral 
ventricles and cortical sulci (Fig. 8b). At 1 year of age, chest X-rays showed the progression 
of interstitial infiltrations and bilateral dense consolidations (Fig. 7b). The child required 
oxygen support during respiratory failure triggered by a viral infection. An MRI of the liver 
revealed an abnormal signal (Fig. 9b-d), but the liver ultrasound was normal (Fig. 9e). A 
nasogastric tube was implanted at the age of 1 year due to feeding problems and progressive 
growth retardation that led to growth arrest. This patient did not present with seizures, and 
electrophysiological examinations were not performed.   
Laboratory investigations revealed chronic haemolytic anaemia: decreased plasma 
haemoglobin (83–95 g/l, reference 100–136 g/l) and blood haematocrit (0.24–0.26, 
reference 0.31–0.42), reticulocytosis (3.46–3.99%, reference 0.8–2.0%), increased plasma 
lactate dehydrogenase (404–707 U/l, reference 150–450 U/l) and a negative Coombs test. 
The blood cell morphology analysis revealed anisocytosis, microcytosis, macrocytosis and 
polychromasia. Plasma alanine aminotransferase was elevated (184–257 U/l, reference 10–
50 U/l), plasma aspartyl aminotransferase was within normal limits (48 U/l, reference ≤ 45 
U/l) and both serum bilirubin (31–36 μmol/l, reference 5–25 μmol/l) and conjugated 
bilirubin (9 μmol/l, reference ≤5µmol/l) were slightly increased. Serum prealbumin (0.24–
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0.27 g/l, reference 0.24–0.42 g/l) and plasma haemoglobin (63 mg/l, reference <100 mg/l) 
were within normal limits while serum haptoglobin (<0.08 g/l, reference 0.29–2.00 g/l) 
was at a lower level. Plasma ammonia (NH4) was normal (37 μmol/l, reference <80 
μmol/l). Furthermore, transient slightly elevated blood lactate (1.61 mmol/l, reference 
0.33–1.33 mmol/l) and slightly elevated blood pyruvate (105 μmol/l, reference 30–80 
μmol/l) were noted, but the lactate/pyruvate ratio was normal (15, reference <25). Serum 
carcinoembryonic antigen (S-CEA) was elevated at 5 months (13.2–22.1 μg/l, reference 
<3 μg/l), and serum neuron-specific enolase (S-NSE) levels were slightly elevated at the 
age of 6 months (20.1–20.4 μg/l, reference <12.5 μg/l). Because of the recurrent infections 
and granulomatosis that occurred in the patient’s older brother, a nitroblue tetrazolium 
(NBT) assay was performed along with other immunological tests. NBT showed normal 
oxidative activity in neutrophils (95.5% versus reference 99.1%) but decreased activity in 
the monocytes (57% versus reference 90.9%). Urinary organic acid analysis revealed that 
ethylmalonic acid levels were slightly elevated.  
At the age of 1 year, the boy’s subcutis was thin, muscle mass was decreased, and 
muscle tone varied from hypotonia to hypertonia and dystonia. He presented with visual 
problems, alternating strabismus, and variable eye contact. The disease course was 
progressive, and the patient died due to respiratory failure at the age of 1 year 1 month after 
treatment at the intensive care unit (ICU) for 7 weeks. 
Family B 
Patient 3 was born at 36 + 1 gestational weeks by emergency caesarean section because of 
a failing heart rate. He was the first child. His mother had undergone ursodeoxycholic acid 
treatment because of gestational hepatosis and toxaemia. The infant’s birth weight was 
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2910 g, and the Apgar score was 10/10. During the first week of life, he was treated twice 
for newborn jaundice with blue light therapy for a total duration of 4 days. ABO 
immunisation was suspected but not proven (serum bilirubin had increased up to 349 
μmol/l at 8 days).  
At 2 months of age, the patient presented with irritability, floppiness and feeding 
problems. Laboratory tests revealed haemolytic anaemia, with decreased plasma 
haemoglobin (69–84 g/l, reference 100–136 g/l) and plasma haematocrit (0.19–0.23, 
reference 0.31–0.42), reticulocytosis (4.0–5.1%, reference 0.8–2.0%), increased plasma 
lactate dehydrogenase (404–643 U/l, reference 150–450 U/l), undetectable plasma 
haptoglobin levels and a negative Coombs test. Blood cell morphology analysis revealed 
polychromasia, anisocytosis, macrocytosis, poikilocytosis and red cell fragments. The 
patient had frequent diarrhoea and poor weight gain. A milk allergy was suspected because 
of the constant diarrhoea, but changes in the formula only slightly improved his diarrhoea.  
At 4 months, the infant presented with a suspected seizure during an influenza B 
infection, and he was hospitalised because of poor general condition, breathing problems 
(gasping for air), and low Sa02 values (70%). Chest X-ray at 4 months of age revealed 
over-inflated lungs and bilateral perihilar interstitial opacities (Fig. 7c).  
At 13 months of age, chest X-rays showed diffuse infiltrates with reticulation (Fig. 
7c). Thoracic HRCT confirmed diffuse bilateral ground-glass opacification, peripheral 
interstitial septal thickening and lobular pleural thickening (Fig. 7c). EEG was normal 
during wakefulness but unusually monotonic during sleep, during which it consisted of 4-
Hertz delta waves without normal sleep spindles and vertex waves.  
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The child continued to be irritable with failure to thrive and, at age 7.5 months, he 
was referred to a neurologist because of slow development. Physiotherapy was started, and 
he was referred to an ophthalmologist because strabismus was noticed. His development 
did not progress.  
 At the age of 8 months, the child suffered almost daily from tachypnoea and cough. 
However, by auscultation, lung sounds were normal. At 10 months of age, he followed 
with his eyes but did not actively grasp toys or turn onto his stomach. He had brisk deep 
tendon reflexes and an indifferent plantar reflex. His breathing was tenuous, and 
tachypnoea was noted. The size of the child’s liver was at the upper limit. Brain MRI 
showed slightly enlarged lateral ventricles and cortical sulci, as well as a thin corpus 
callosum. T2-weighted axial MRI revealed a mildly increased signal intensity of the globus 
pallidi (Fig. 8c).  
The child underwent gastrostomy because of weight loss. Blood lactate was 
intermittently elevated (1.685–3.93 mmol/l, reference 0.33–1.33 mmol/l), and the plasma 
lactate/pyruvate ratio was at an increased level (35, reference <25). Serum thyroid-
stimulating hormone (TSH) was slightly decreased (0.5–0.87 kU/l, reference 1.3–8.5 kU/l), 
but serum thyroid hormone levels (free T4 and T3) were normal. Immunological tests 
revealed that serum immunoglobulin G was slightly diminished (1.1–1.6 g/l, reference 2.7–
10.1 g/l). In one instance, urinary organic acid analysis indicated small amounts of 
dicarboxylic acids without ketone bodies. Otherwise the extensive metabolic screening was 
normal. The child’s breathing difficulties became progressively worse, and he died due to 
respiratory failure at 1 year 2 months of age after being treated at the ICU for 5 weeks. 
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Copy number variants and large regions of homozygosity were studied by 
HumanCytoSNP-12 (v2.1) (Illumina, San Diego, California, USA).  The results were 
normal and no pathogenic variation was detected in Patient 3. 
 
Methods 
Histopathological studies of tissue samples  
Tissue biopsies (lung and skeletal muscle biopsies) and autopsy samples were obtained 
from all three patients. The tissue was fixed in buffered 4% formaldehyde, routinely 
processed into paraffin blocks and cut into 5.0 μm sections. For immunohistochemistry, 
the sections were deparaffinised in xylene, rehydrated through graded ethanol, and stained 
with the following antibodies from Dako/Agilent Technologies (Santa Clara, CA, USA): 
CD68 (clone PG-M1, 1:100 dilution, Dako code M0876), Ck-PAN (Clone MNF-116, 
1:700 dilution, Dako code M0821), caldesmon (clone h-CD, dilution 1:1000, Dako code 
M3557), alpha-smooth muscle actin (clone 1A4, dilution 1:500, Dako code M0851), and 
smooth muscle myosin heavy chain (SMMHC) (clone SMMS-1, dilution 1:100, Dako code 
M3558).  
 
DNA extraction  
Total genomic DNA from the blood samples of the patients and their family members, as 
well as from the patients’ fibroblasts, was extracted with the QIAamp DNA Mini Kit 
(Qiagen, Hilden, Germany). Saliva samples were collected from the family members of the 
affected children using Oragene DNA Collection kits (DNA Genotek, Ottawa, Canada) 
and the prepIT L2P kit (DNA Genotek, Ottawa, Canada) was used for DNA extraction. For 
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the Northern Finnish population controls, DNA was extracted from umbilical cord blood 
with the UltraClean DNA Blood Isolation Kit (MO BIO Laboratories, Carlsbad, CA, 
USA). For a subset of the samples, whole-genome amplification was performed, as 
previously described [4]. 
 
 
Whole-exome sequencing and bioinformatics  
Next-generation sequencing library preparation, enrichment, and sequencing were 
performed using the Nimblegen V2 Exome 
(http://www.nimblegen.com/products/seqcap/ez/v2/) at the Technology Centre of the 
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, as previously 
described [13]. DNA from the affected patients and their parents was also analysed by 
exome sequencing. Bioinformatics analysis was performed, as previously described [16].
 
Briefly, the Burrows-Wheeler Aligner (BWA v. 0.5.9) was used to map all reads to UCSC 
hg19. PCR duplicates were removed from alignments using Picard version 1.87 
(http://broadinstitute.github.io/picard/). Indels were realigned with the Genome Analysis 
Toolkit (GATK 1.0.5083). SAMtools version 0.1.18 was used to call the variants. All 
variants were annotated with ANNOVAR and in-house scripts, and the most likely protein 
damage variants (nonsense, splice-site, frame shift, indel and missense) were considered 
for further analysis. The variants were also annotated for allele frequency in public 
databases such as Exome Aggregation Consortium (ExAC) 
(http://exac.broadinstitute.org/); the National Heart, Lung, and Blood Institute (NHLBI) 
exomes (V.0.0.14, http://evs.gs.washington.edu/EVS/); the 1000 Genomes Project 
database (http://www.internationalgenome.org) and our in-house database of >1,000 
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exomes. To remove common variants and sequencing artefacts, variants with minor allele 
frequencies of >0.01 in any of the aforementioned databases were removed from further 
analysis. The only candidate gene that was common to both families was NHLRC2.  
 
Variant analysis and genealogy of the two families  
Using Sanger sequencing, we confirmed variants and segregation within the families. The 
region encompassing the two NHLRC2 variants was amplified by PCR with the primers 5 
′-TGG TGT TCA CTC GGC TAA GT-3′ and 5′-GTC CAT TCT TCC AAA CGA CCA-
3′ and then sequenced. To investigate the descent of the variants, we performed a 
genealogical study in accordance with published criteria [14].
 
We traced the ancestors of 
the patients from the Finnish Population Registries and scrutinised the microfiche copies 
available in the National Archives of Finland.  
 
Fibroblast cultures  
Fibroblasts from healthy individuals and patients were grown at 37°C in an atmosphere of 
5% CO2 in high-glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (Corning, 
Manassas, VA, USA) supplemented with 10% foetal bovine serum. The patient and control 
cell lines were transduced with a retroviral vector expressing the E7 gene of  type-16 human 
papilloma virus and a retroviral vector expressing the protein component of human 
telomerase to immortalise the cells [17]. 
  
RNA extraction from fibroblasts  
We used trypsin (Lonza, Verviers, Belgium) to harvest 1 × 10
7 
cultured fibroblasts from 
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healthy individuals and patients. Total RNA was extracted with the RNeasy Plus Mini kit 
(Qiagen, Hilden, Germany). After reverse-transcription PCR (RT-PCR), we used Sanger 
sequencing to investigate the expression of the mutant alleles. The OneStep RT-PCR kit 
(Qiagen, Hilden, Germany) was used for the patients’ cDNA analysis by qPCR. 
 
qPCR to measure the expression of NHLRC2 mRNA 
qPCR was performed according to the manufacturer’s instructions (IQTM SYBR Green 
Supermix, Bio-Rad, Hercules, CA, USA) using a CFX ConnectTM Real-Time System (Bio-
Rad, Hercules, CA, USA). Melting temperature (Tm) of the analysis was adjusted to 61°C, 
and TATA-Box Binding Protein (TBP) and Glucuronidase Beta (GUSB) were chosen as 
endogenous control genes.  Primers 5´-CAGACCTCGCTAGAGTACGC-3´ and 5´-
GTTCAGCCATTCTAATCCTTCCG-3´ were used for NHLRC2, 5´- 
GTCTGCGGCATTTTGTCGG-3´ and 5´-CACACGATGGCATAGGAATGG-3´ for 
GUSB and 5´-CCACTCACAGACTCTCACAAC-3´ and 5´-
CTGCGGTACAATCCCAGAACT-3´ for TBP (Primer bank IDs 304307770c1, 
268834191c1 and 285026518c1) [11,12,15].  
 
Immunoblotting  
Protein expression in the whole-cell extracts of the fibroblasts from all three patients and 
healthy control subjects, together with the homogenates of control autopsy samples from 
several types of human tissues, were analysed by immunoblotting. Whole-protein extracts 
from the fibroblasts were prepared in 1.5% n-dodecyl maltoside (Sigma-Aldrich, St. Louis, 
MO, USA) in phosphate-buffered saline (PBS). Proteins from the whole-cell extracts and 
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tissue homogenates were precipitated with ethanol and a total of 20–100 μg of protein per 
sample was used for Tris-glycine SDS-PAGE (4–20% Precise Protein Gel; ThermoFisher 
Scientific, Waltham, MA, USA). Proteins were transferred to a nitrocellulose membrane 
(Amersham Hybond ECL; GE Healthcare, Buckinghamshire, UK). Mouse polyclonal 
antibodies against full-length human NHLRC2 (SAB1400871, Sigma-Aldrich, St. Louis, 
MO, USA; NBP1-85019, Minneapolis, MN, USA; ab88725, Abcam, Cambridge, UK) and 
against GAPDH (GeneTex, Irvine, CA, USA) were used, together with secondary 
antibodies (ThermoFisher Scientific, Waltham, MA, USA) to visualize the proteins by 
enhanced chemiluminescence (ECL) (GE Healthcare, Buckinghamshire, UK). Signal 
intensities were quantified (ImageJ) and the level of NHLRC2 was compared to the level 
of GAPDH [10]. 
 
Expression of human NHLRC2 in tissue  
Autopsy tissue specimens from human heart, kidney, skeletal muscle, liver, lung and brain 
were homogenised to examine the overall expression of NHLRC2 in tissues. Tissue (5 mg) 
was dissected on ice, ’snap frozen’ in liquid nitrogen and homogenised in 300 μl of ice-
cold 20 mM Tris-HCl (pH 7.5) with Pierce protease inhibitors (ThermoFisher Scientific, 
Waltham, MA, USA). Homogenates were maintained with constant agitation for 2 hours 
at 4°C and centrifuged for 20 minutes at 13,500 × g at 4°C in a microcentrifuge (Eppendorf, 
Hamburg, Germany). Protein concentrations were measured from supernatants with the 
Coomassie Protein Assay kit (ThermoFisher Scientific, Waltham, MA, USA). Due to rapid 
autolysis of the lung and brain samples, the amount of total protein obtained from these 
autopsy specimens was low and required precipitation with ethanol prior to 
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immunoblotting.  
 
Cloning of human NHLRC2 in E. coli  
A gene that encodes full-length human NHLRC2 and is a codon optimised for E. coli 
expression was purchased from GenScript (Piscataway, NJ, USA). The domain 
organisation of human NHLRC2 (M1-F726) is defined in InterPro [6] as having an N-
terminal thioredoxin-like domain (Q43-D200) and a six bladed beta-propeller (G210-
P592). Based on this information plus secondary structure prediction [1], structural 
homology searches and sequence analysis, we predicted that the protein contained both 
domains, with the thioredoxin-like domain having an -helical N-terminal extension and 
ending around G202 and the beta-propeller domain starting around P222. The region 
between the two could belong to either or neither domain. Accordingly, we made a series 
of domain constructs to express the full-length protein and fragments in E.coli. The DNA 
fragments encoding these constructs were amplified by PCR with primers that were 
designed to include NdeI and BamHI restriction sites on the 5′ and 3′ ends, respectively. 
The PCR fragments were digested with the corresponding enzymes and ligated into a 
modified variant of pET23 with the T7 promoter replaced by Ptac [2]. All plasmids 
generated were sequenced to ensure there were no errors in the cloned genes.  
 
Expression and purification of full-length human NHLRC2 protein and thioredoxin-
like domain of NHLRC2 
Sixteen NHLRC2 constructs were expressed in E. coli strain BL21 (DE3) with EnPresso®B 
medium (BioSilta, Cambridgeshire, UK) in accordance with the manufacturer’s 
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instructions. From the analysis of the constructs made, the predicted domain boundaries 
were correct, and the linker region was better behaved when part of the thioredoxin domain 
than when only part of the beta-propeller domain. Accordingly, two constructs were used 
for larger scale protein production and analysis. The first construct contained the gene 
encoding the full-length human NHLRC2 (M1-F726) protein while the second contained 
DNA corresponding to the NHLRC2 thioredoxin-like domain (M1-S221). Briefly, BL21 
(DE3) cells were transformed with the appropriate construct and plated onto Luria-Bertani 
(LB) agar plates containing 100 μg/ml ampicillin. Plates were incubated overnight at 37°C. 
The next morning, several colonies were transferred into 5 ml of LB medium supplemented 
with 100 μg/ml ampicillin. Cultures were grown at 30°C with shaking at 200 rounds per 
minute (rpm) for 6 hours. Five millilitre aliquots of preculture were used to seed 500 ml of 
EnPresso®B with 100 μg/ml ampicillin in 5 L Erlenmeyer flasks. Cultures were incubated 
at 30°C with shaking at 250 rpm for approximately 16 hours.  
Protein production was induced by the addition of 250 μM Isopropyl β-D-1-
thiogalactopyranoside (IPTG), and booster media was added. Cells were harvested by 
centrifugation (3,220 x g, 20 min) after 24 hours of incubation at 30°C. Cells were 
resuspended in a lysis buffer (50 mM sodium phosphate [pH 7.4], 500 mM NaCl, 5% 
glycerol, and 10 mM imidazole) supplemented with PierceTM Protease Inhibitors EDTA-
free (ThermoFisher Scientific, Waltham, MA, USA), 0.1 mg/ml lysozyme and 20 μg/ml 
DNAse. Cells were lysed using three cycles of freeze-thawing. Cell debris was removed 
by centrifugation, and the soluble fraction was loaded onto a 5 ml HiTrap HP column (GE 
Healthcare, Buckinghamshire, UK). Specifically, bound proteins were eluted from the 
column with increasing concentrations of imidazole. All the collected fractions were 
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analysed by SDS-PAGE. Fractions containing the protein of interest were pooled together 
and dialysed against 20 mM Tris (pH 8.0), 25 mM NaCl and 2 mM Dithiothreitol (DTT). 
Dialysed protein solution was loaded into a Q HiTrap (GE Healthcare, Buckinghamshire, 
UK), and the protein of interest was eluted with increasing concentrations of NaCl. Full-
length NHLRC2 was additionally purified by size-exclusion chromatography on a 
Superdex 200 column (GE Healthcare, Buckinghamshire, UK). Samples containing full-
length NHLRC2 or the thioredoxin-like domain were concentrated to 9.2 and 7.5 mg/ml, 
respectively, flash-frozen in liquid nitrogen, and stored at -70°C.  
 
Insulin assay  
The insulin turbidity assay to test for thioredoxin activity was performed, as previously 
described [3].
 
Briefly, the assay was done in 200 μl of 0.1 M sodium phosphate buffer (pH 
7.0) with 1 mM EDTA and 10 mM DTT, as well as 1μM enzymes when appropriate. The 
reaction was started by the addition of 1 mg/ml insulin and monitored at 540 nm for 30 
minutes. Measurements were taken every 30 seconds, and the lag phase for precipitation 
was monitored. E. coli thioredoxin was used as a positive control in the assay and was 
produced as previously described [8]. 
 
Culturing of Nhlrc2
tm1a 
mouse morulae  
The mating of heterozygous female and male mice was confirmed by the presence of a 
vaginal plug. On embryonic day 2.5 (E2.5), morulae were flushed from the uterus in 
accordance with a previously described protocol [7].
 
The uterus was cut near the cervix, 
and a 27 G needle attached to a 3 ml syringe was inserted into the oviduct. Both uterine 
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horns were flushed with PrimeQTM M2 Mouse Embryo Culture Medium (Amsbio, 
Abingdon, UK). The morulae were transferred into a micro-culture drop of PrimeQTM 
KSOM Mouse Embryo Medium (Amsbio, Abingdon, UK), covered with embryo-tested 
light mineral oil (Merck-Sigma, Temecula, CA, USA) and equilibrated in an organ culture 
incubator (37°C, 5% CO2). Embryos grown overnight in the microculture drop were 
transferred onto a gelatinized 24-well plate, each into its own well with 300 µl of 
embryonic stem cell medium, and left to grow for 10–12 days, after which DNA was 
extracted, as described [9]. 
 
Genotyping of Nhlrc2
tm1a 
knockout mouse offspring and embryos 
Primers CAS_R1_Term, Nhlrc2_119354_F, Nhlrc2_119354_R, LacZ_probe_F, and 
LacZ_probe_R (https://www.infrafrontier.eu/search?keyword= Nhlrc2) were used with 
Phire Hot Start II Polymerase (ThermoFisher Scientific, Waltham, MA, USA) for 
genotyping.  
 
X-gal staining  
To demonstrate LacZ expression in the embryos, E14.5 Nhlrc2
tm1a 
heterozygote mutant 
embryos were dissected in ice-cold PBS and fixed at room temperature for 30 min in a 
solution containing 0.2% glutaraldehyde, 2 mM MgCl2, 5 mM EGTA and 0.1 M kanolinite 
phenylphosphonate (KPP) (pH 7.3) in water. They were then washed three times for 10 
min in 0.02% Nonidet P-40, 0.01% Na-deoxycholate, 5 mM EGTA, 2 mM MgCl2 and 0.1  
M KPP pH 7.3 in water and stained by incubating in a 5-bromo-4-chloro- 3-indolyl β-D-
galactopyranoside staining solution (X-gal, #R0402; ThermoFisher, Waltham, MA, USA) 
18 
18 
 
composed of 10 mM K3Fe(CN)6, 10 mM K4Fe(CN)6 and 1 mg/ml X-gal in DMSO at room 
temperature overnight. The embryos were thereafter fixed with 4% paraformaldehyde.  
 
Generation of zebrafish morphants 
Two morpholinos against the zebrafish nhlrc2 (ENSDARG00000089581) were designed; 
the first morpholino was against the ATG-site to prevent translation, and the second one 
was against the exon-intron boundary at the 3’ end of exon 4 (ENSDARE00000919598) to 
prevent splicing, which both would lead to a frameshift and premature termination of 
translation. The regions were sequenced for polymorphism before morpholino design. 
Morpholino sequences were 5’-ACCCGATTCTGCTGATTTACCTTTC-3’ (splice site 
blocking) and 5’-CTGTCAGCTTACTGTAAGACGCCAT-3’ (translation blocking) 
(GeneTools, LLC, Philomath, OR, USA). 
The morpholinos were heated to 65ºC before use to achieve complete suspension. 
Then, 1 nl of each morpholino (1.0– 5.0 ng) in a solution containing PBS and 0.2% 
rhodamine B (Sigma-Aldrich, St. Louis, MO, USA) was injected into a 1-2 cell stage 
embryo using a microinjector (PV830 Pneumatic PicoPump, World Precision Instruments, 
Sarasota, FL, USA). The morphant embryos were screened for fluorescence (570/590 nm 
excitation/emission) 4 hours post fertilization (hpf), and images were taken at 24, 48, 72 
and 96 hpf with a fluorescence microscope (Zeiss Lumar V12, Carl Zeiss, Oberkochen, 
Germany). A standard random control morpholino and a p53 morpholino (GeneTools, 
LLC, Philomath, OR, USA) were used to control the non-specific effects of the 
morpholinos. WT AB zebrafish embryos were maintained according to standard protocols. 
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Quantitation of knockdown 
The effect of the splice site-blocking morpholino for nhlrc2 levels was quantified using 
PCR. Primers were designed on exon 3 and exon 5 to detect the loss of exon 4 (forward 
primer 5’-GTCTCCAATACTGGGCAGGTG-3’ and reverse primer 5’-
GCCTGCTAATGTTGAGACTTTTCC-3’). Because an effective antibody against 
zebrafish Nhlrc2 was not available, the effect of the translation-blocking morpholino could 
not be evaluated. 
RNA extractions were done from four to seven pooled embryos using Tri reagent 
(Molecular research centre, OH, USA), and 70-300 ng of the RNA was used for cDNA 
synthesis using a SensiFAST cDNA synthesis kit (Bioline, Taunton, MA, USA) according 
to the manufacturer’s instructions. The obtained RNA was treated with DNase I (Thermo 
Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Then, 70-
300 ng DNase-free RNA was used for cDNA synthesis using SensiFAST cDNA synthesis 
kit (Bioline, Taunton, MA, USA) according to the manufacturer’s instructions. The cycling 
conditions for PCR (SsoFast Evagreen Supermix, Bio-Rad, Hercules, CA, USA) were 95ºC 
3:00, 95ºC 0:02, 59ºC 0:05 and 59ºC for 0:10, and a melt curve with an increment of 0.5ºC 
to 95ºC. 5 µl of the product was run on 2% agarose gel with 1:10 000 SybrSafe DNA gel 
stain (Thermo Fischer Scientific, Waltham, MA, USA). The knockdown efficiency was 
determined from an agarose gel using ImageJ v1.49 by calculating the ratio of the WT, 
unmodified band to the sum of all the bands on a single lane (WT and two morpholino 
modified bands corresponding to exon exclusion and intron inclusion caused by splice site 
blocking). 
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Timing of Dechorionation  
Dechorionation of the embryos was recorded every 3 hours between 36 hpf and 53 hpf and 
then at 60 hpf and 70 hpf.  
 
Supplementary figures 
 
Fig. 7 Radiological findings of chest X-rays and high-resolution computed tomography of 
Patients 1–3. a Patient 1 at 7 months of age shows flattened hemidiaphragms and 
hyperlucent lungs demonstrating over-inflated lungs, small air-filled bullae of the right 
mediobasal lung (short arrows) and perihilar small atelectasis (long arrow). Performed 
during an acute metabolic crisis at the age of 9 months, the chest X-ray demonstrates 
perihilar and basal airspace opacities and axial HRCT confirms bilateral consolidations 
(long arrows) and reticular opacities (short arrows). b Patient 2 at 4 months of age 
demonstrates mediastinal and hilar prominence (short arrows), over-inflated lungs, and 
diffuse reticular interstitial opacities. At 4 months of age, HRCT reveals widespread 
bilateral ground-glass opacities (short arrow), interstitial infiltrations (long arrows) and 
atelectasis (black arrowhead), mildly enlarged thymus (white arrowhead) and left hilar 
adenopathy (asterisk). At 1 year of age, chest X-rays show the progression of interstitial 
infiltrations and bilateral dense consolidations (long arrows). c Patient 3 at 4 months of age 
reveals over-inflated lungs and bilateral perihilar interstitial opacities (short arrows). At 13 
months of age, the chest X-ray shows diffuse infiltrations with reticulation. HRCT 
confirms diffuse bilateral ground-glass opacification, peripheral interstitial septal 
thickening and lobular pleural thickening (long arrows) 
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Fig. 8 Findings from brain magnetic resonance imaging of Patients 1–3. a Sagittal T1-
weighted magnetic resonance imaging (MRI) shows the thin corpus callosum of Patient 1 
at 7 months of age. b Patient 2 at 10 months of age. c Patient 3 at 10 months of age (short 
arrows). The axial T2-weighted and coronal T1-weighted MRIs of Patients 2 (b) and 3 (c) 
demonstrate slightly dilated lateral ventricles and cortical sulci. c Increased signal intensity 
of the globus pallidus on the axial T2-weighted MRI of Patient 3 (arrowheads) 
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Fig. 9 Findings from abdominal ultrasound and magnetic resonance imaging of internal 
organs and thymus of Patients 1 and 2. a The abdominal ultrasound findings (Patient 1 at 
10 months of age) show increased cortical echogenity with the strand-like hypoechogenic 
outerzone of both kidneys (short arrows). b The abdominal T2-weighted axial MRI of 
Patient 2 at 4 months of age shows hepatomegaly and a non-expansive hypointense lesion 
of the right liver lobe (long arrows). c The lesion is also hypointense on the T1-weighted 
coronal MRI (long arrows). d The axial fat saturation T1-weighted MRI of Patient 2 shows 
that the lesion (arrowheads) in the liver is less enhanced by the gadolinium contrast agent 
than the rest of the liver. e Normal echogenity of the right liver lobe of Patient 2 at the age 
of 4 months. f A slightly enlarged thymus of Patient 2, which was seen in the coronal T1-
weighted MRI (asterisk) 
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Fig. 10 a Electropherograms showing both heterozygote NM_198514:c.442G>T and 
c.601_602delAG variants in genomic DNA from the patient. b The RNA extracted from 
the patients’ fibroblasts has only c.442G>T. Thus, Sanger sequencing of mRNA confirms 
that the variants reside in separate haplotypes and have been inherited as compound 
heterozygotes in all patients. Furthermore, the absence of the c.601_602delAG variant 
indicates that the transcript with the frameshift deletion is processed through nonsense 
mediated RNA decay  
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Fig. 11 Immunoblotting to detect NHLRC2 protein expression in human tissue 
homogenates from control autopsy samples. NHLRC2 was detected in all studied human 
organs including the heart (He), kidney (Ki), muscle (Mu), liver (Li), lung (Lu) and brain 
(Br). GAPDH was used as a loading control 
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Fig. 12 Nhlrc2 is expressed in various cell types of the mouse brain and NHLRC2 
expression is highest in the early human life.  a An RNA-Seq transcriptome and splicing 
database of the glia, neurons and vascular cells of the cerebral cortex show the highest 
Nhlrc2 expression in astrocytes, oligodendrocyte progenitor cells, newly formed 
oligodendrocytes and endothelial cells. Nhlrc2 was also expressed in neurons, myelinating 
oligodendrocytes and microglia. (OPG) oligodendrocyte progenitor cells [18]. 
Abbreviations: FPKM, fragments per kilobase per million.  b The average expression levels 
of NHLRC2 are similar between the cerebellar cortex (CBC), mediodorsal nucleus of the 
thalamus (MD), striatum (STR), amygdala (AMY), hippocampus (HIP) and 11 areas of the 
neocortex (NCX) in the human brain (http://hbatlas.org/). c The expression is highest in the 
early development of the human brain. The number of samples is indicated on the top of 
the x-axis. Data from www.brainspan.org [5]. Abbreviations: RPKM, reads per kilobase 
per million; pcw, post conception week; mos, months; yrs, years  
a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b 
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Fig. 13 Wild-type (WT) and heterozygous (het) Nhlrc2 KO morulae and their growth in 
vitro. The morulae were isolated at embryonic day (E) 2.5 and co-cultured in a micro drop 
culture overnight. On the next day, the E3.5 compacted morulae and early blastocysts were 
transferred to separate gelatinised wells. At E4.5, the embryos had matured to the blastocyst 
stage and at E5.5 they hatched and attached to the bottom of the plate. Cells were grown 
for several days to detect possible phenotypes and to obtain enough material for genotyping 
(E7.5, E10.5 and E13.5). No homozygous morulae were detected  
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Fig. 14 nhlrc2 splice site-blocking morpholino alters the mRNA spicing in zebrafish 
embryos but not the gross morphology of the embryos. Indicated amount of splice site 
targeting morpholino (together with an equal amount of p53 morpholino) was injected into 
the yolk sacs of fertilised eggs at the 1-2 cell stage. a Arrows on the left show the expected 
product sizes after the splice site-blocking events (334 bp intron inclusion, 198 bp WT 
product, 76 bp exon exclusion), and below the image are indicated the times of RNA 
extraction as days post fertilisation (dpf). b Un-injected controls on the left, nhlrc2 splice 
site-blocking morpholino (3.6 ng) treated morphants in the middle and nhlrc2 translation-
blocking morpholino (2.3 ng) treated morphants on the right. The embryos appear to have 
WT morphology; only minor swelling was observed in the abdominal area in some 
individuals in both morphant groups at 3 dpf. However, this swelling diminished by 4 dpf. 
The images were taken with Axiovision software version 4.8 using a Zeiss SteREO Lumar 
V12 fluorescence microscope, equipped with 1.5X camera (Carl Zeiss MicroImaging 
GmbH, Göttingen, Germany) 
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Fig. 15 The timing of dechorionation of the nhlrc2 morphants. The fraction of 
dechorionated embryos was recorded for selected hours post fertilisation (hpf). The 
significances were calculated with a log rank Mantel-Cox test. PBS control N=91, 
untreated control N=47; p53 MO control N=23; untreated control N=36; random control 
MO 3.6 ng N=63; untreated control N=34 and splice site-blocking MO 3.6 ng N= 76, 
untreated control N=34. Graphs were generated with GraphPadPrism 5 
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Fig. 16 Knockdown of nhlrc2 using splice site-blocking morpholino (nhlrc2 SB MO), 
translation-blocking morpholino (nhlrc2 TB MO), a combination (nhlrc2 SB+TB MO) of 
the two morpholinos compared to un-injected controls (Control) and random control 
morpholino (RC MO). a nhlrc2 splice site blocking morpholino alters the mRNA splicing 
in zebrafish embryos. The indicated amount of splice site-targeting morpholino (together 
with an equal amount of p53 morpholino) was injected into the yolk sacs of fertilised eggs 
at the 1-2 cell stage. After the indicated time, RNA was isolated, PCR was performed and 
PCR product was run on 2% agarose gel. Arrows on the left annotate the expected product 
sizes after the splice site-blocking events (334 bp intron inclusion, 198 bp WT product, 76 
bp exon exclusion), and below the image are the times of RNA extraction as days post 
fertilisation (dpf). b Knockdown efficiencies were calculated using ImageJ 1.49v. The 
levels of WT transcript are displayed above the bars for samples containing splice site-
blocking morpholinos 
a  
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